Of the top 10 pharmaceutical companies by revenue in 2017, 9th is Gilead Sciences. (source) Gilead makes an interesting subject for business development professionals, as they are cash heavy and must develop or acquire new blockbuster drugs before current revenue-producers wane or their patent protection expires.
Gilead Sciences, Inc.
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: $9809M USD
Therapeutic Focus: HIV/AIDS, Liver Diseases, Hematology/Oncology, Inflammation/Respiratory, Infectious Diseases
Figure 1. Gilead Sciences, Inc. In-Licensing Deals and Acquisitions, 2012 through Present (July 2017)
ACQUISITION OF NIMBUS THERAPEUTICS ACETYL-COA CARBOXYLASE (ACC) INHIBITOR PROGRAM
GLOBAL PARTNERSHIP WITH GALAPAGOS TO DEVELOP FILGOTINIB JAK1 INHIBITOR
ACQUISITION OF EPITHERAPEUTICS LIBRARY OF FIRST-IN-CLASS, SELECTIVE SMALL MOLECULE INHIBITORS OF EPIGENETIC REGULATION OF GENE TRANSCRIPTION
Figure 2. Gilead Sciences, Inc. R&D Pipeline at present (July 2017)
ACQUIRED NIMBUS THERAPEUTICS ACC INHIBITOR PROGRAM
Disease Area: Liver Disease | Status: NASH Phase II
GALAPAGOS PARTNERED FILGOTINIB JAK1 INHIBITOR
Disease Area: Inflammation / Respiratory | Status: Rheumatoid Arthritis Phase III | Crohn's Disease Phase III | Ulcerative Colitis Phase III | Active Non-Infectious Uveitis Phase II
Disease Area: Oncology | The status of these acquired pre-clinical assets is unclear.